Feb. 11, 2022

Every tumor is a deadly frontier, and to survive it you need a personalized, therapeutic path forward. Enter the AI-centric guidance of Evaxion’s, PIONEER

Every tumor is a deadly frontier, and to survive it you need a personalized, therapeutic path forward. Enter the AI-centric guidance of Evaxion’s, PIONEER
Spotify podcast player badge
Apple Podcasts podcast player badge
Pandora podcast player badge
RSS Feed podcast player badge
Spotify podcast player icon Apple Podcasts podcast player icon Pandora podcast player icon RSS Feed podcast player icon

Every cancer neoantigen prediction platform has lots and lots of math – the PIONEER platform, from the Danish company, Evaxion, has data. In a phase I/IIa study in metastatic melanoma the ORR was 67%, and two patients with stable disease converted to complete responders. Investors take note, because Merck sure did… Dr. Lars Wegner, CEO of Evaxion fills in the details.